3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Basal Cell
5
Skin Neoplasms
3
Basal Cell Nevus Syndrome
3
Recurrence
2
Multiple Myeloma
2
Medulloblastoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hematologic Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Paclitaxel
34
Carboplatin
27
pembrolizumab
20
Bevacizumab
16
Letrozole
13
Megestrol Acetate
10
Cisplatin
9
lenvatinib
8
olaparib
7
dostarlimab
7
Metformin
7
durvalumab
6
abemaciclib
6
Radiotherapy
6
Everolimus
6
niraparib
5
Specimen Handling
5
Nivolumab
5
Medroxyprogesterone Acetate
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
Fluorouracil
5
Docetaxel
5
Biopsy
5
temsirolimus
4
rucaparib
4
Oxaliplatin
4
Fulvestrant
4
Doxorubicin
4
sapanisertib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Endometrial Neoplasms
×
sonidegib
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts